[Form 4] SCYNEXIS, Inc. Insider Trading Activity

Rhea-AI Filing Summary

SCYNEXIS, Inc. (SCYX) – Form 4 insider transaction

Non-employee director Armando Anido reported two equity awards granted on 26 June 2025:

• 23,000 restricted stock units (RSUs) of common stock at a deemed price of $0 (code “A”). All RSUs vest 100 % on the first anniversary of the grant, contingent on continued board service. Post-grant, Anido holds 71,000 directly owned shares.
• Stock option for 23,000 shares with an exercise price of $0.74, expiring 25 June 2035. The option also vests 100 % after one year of service.

The filing signals additional equity-based alignment between the director and shareholders but represents a routine non-cash compensation grant rather than an open-market purchase. No sale or disposition occurred, and no immediate cash outflow by the company is disclosed. The total potential dilution from the awards is immaterial relative to SCYNEXIS’s outstanding share count.

Positive

• Additional insider equity ownership may strengthen alignment between the director and shareholders.

Negative

• No open-market purchase; therefore, the transaction offers limited conviction signal to investors.

Insights

Securities Analyst

TL;DR: Routine director equity grant; modest insider alignment, minimal dilution, no immediate valuation impact.

The RSU and option grants increase Mr. Anido’s stake but are standard board compensation. Because the RSUs were priced at zero and the option strike is only $0.74—near penny-stock levels—the awards embed upside if SCYX recovers, modestly aligning incentives. However, the grants do not involve open-market cash purchases, so the signaling power is limited. The aggregate 46k-share award is immaterial compared with SCYX’s float, so dilution is negligible. Overall impact is neutral from an investment thesis perspective.

Corporate Governance Expert

TL;DR: Grants follow typical one-year cliff vesting; governance practices appear standard.

The one-year cliff vesting for both RSUs and options is customary for small-cap biotech boards, encouraging retention without excessive long-dated overhang. The 10-year option term is mainstream. No red flags on disclosure, timing, or 10b5-1 plan usage. Because compensation is equity-based, it conserves cash, appropriate for development-stage firms. Investors should watch future grants to ensure cumulative dilution stays within plan limits.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANIDO ARMANDO

(Last) (First) (Middle)

1 EVERTRUST PLAZA

13TH FLOOR

(Street)

JERSEY CITY NJ 07302-6548

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SCYNEXIS INC [ SCYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		A		23,000(1)	A	$0	71,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.74	06/26/2025		A		23,000		(2)	06/25/2035	Common Stock	23,000	$0	23,000	D

Explanation of Responses:

1. One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

2. One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

	/s/ Robert F. Joyce Jr., by Power of Attorney	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SCYX shares did director Armando Anido receive on 26 June 2025?

He received 23,000 restricted stock units and an option on 23,000 shares.

What is the exercise price and expiration of the new SCYX stock option?

The option is exercisable at $0.74 per share and expires on 25 June 2035.

How many SCYX shares does the director own after the reported grant?

Following the grant, the director beneficially owns 71,000 shares directly.

When do the RSUs and options granted to the SCYX director vest?

Both the RSUs and options vest 100 % on the first anniversary of the 26 June 2025 grant date.